Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 491

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 491
---
 segmentation and profiling: Understand how to group physicians based on their prescription practices 
 and other behaviors and factors that will influence their prescription practices.                        |

| • |     | Patient segmentation and profiling: Divide patients with sciatica into groups, according to gender,                                              
 insurance type, state of disease, and any other factors that will help identify ways to increase SP-102’s utilization in each group of patients. |

| • |     | HCP and patient research: HCP research on how physicians treat sciatica, what are the unmet needs, what                                                                                                                                                  
 type of product physicians want to use to treat sciatica, and their expectations from the new product. Patient research provides us with information regarding how satisfied patients are with the current treatments, where the current treatments fall 
 short, and their expectations on the new treatments.                                                                                                                                                                                                     |

| • |     | Marketing conditioning campaign development: Determine how to condition the market, including by                                                                 
 identifying the current short falls and unmet needs in current treatments, ways to highlight these prior to launch, and the expectations for the new treatments. |

| • |     | Product positioning: Position the product by highlighting physician feedback on the product (e.g., safety, 
 efficacy and length of effectiveness).                                                                     |

| • |     | Branded campaign development and testing: Develop key messages around the benefits of SP-102. |

| • |     | Campaign materials and temporary billing/coding reference guide: Develop materials for launch and       
 promotion of SP-102 and develop billing codes guidelines for physicians to charge insurance for SP-102. |

| • |     | Omnichannel promotion material development: Develop promotion materials for various channels, ensuring a                                                                              
 consistent message, design and tone. These materials could include materials to sales representatives, journal advertisement, direct communication to patient and congress materials. |

| • |     | Trade name submission to FDA: Submit the trade name to FDA prior to filing NDA. |

| • |     | OPDP submission strategy: Submit launch materials to FDA based on the approved prescribing label. |

| • |     | Packaging research: Conduct research on packaging methods with customers, including pharmacists,                     
 physicians, nurses, and people who handle the product, to ensure the packaging is convenient for those using SP-102. |

| • |     | Baseline/Pre-launch HCP ATU: Based on product profile messaging,                                                                                                                                          
 discuss with physicians how they intend to prescribe the product to patients, what key messages resonate with them, and their awareness of SP-